Data from Pharmawand - Curated by EPG Health - Date added 16 November 2018

Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for Cabometyx (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx in this indication in all 28 member states of the European Union, Norway and Iceland.

The EC approval is based on results from the CELESTIAL trial of Cabometyx in patients with advanced HCC who received prior sorafenib. In this phase III pivotal trial, Cabometyx demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo. Cabometyx is also approved in the European Union for the treatment of advanced renal cell carcinoma (RCC) in adults who have received prior VEGF-targeted therapy and for previously untreated intermediate- or poor-risk advanced RCC.

Comment: On May 29, 2018, Exelixis announced that the FDA accepted for filing the supplemental New Drug Application (sNDA) for Cabometyx for previously treated advanced HCC and assigned a Prescription Drug User Fee Act action date of January 14, 2019.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Related Content